Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering TopBuild (BLD) , which belongs to the Zacks Building Products - Miscellaneous industry.When looking at the last two reports, this insulation products company has recorded a strong streak of surpassing earnings estimates. The company has topped estimates by 3.71%, on average, in the last two quarters.For the last reported quarter, TopBuild came out with earnin ...

Wall Street expects a year-over-year increase in earnings on higher revenues when TG Therapeutics (TGTX) reports results for the quarter ended December 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the ...

Core Viewpoint - Life360 (LIF) is anticipated to report a year-over-year increase in earnings driven by higher revenues, with the consensus outlook indicating a significant potential impact on its stock price based on actual results compared to estimates [1][2]. Earnings Expectations - The upcoming earnings report is expected to show quarterly earnings of $0.33 per share, reflecting a year-over-year increase of +230% [3]. - Revenues are projected to reach $144 million, which is a 24.6% increase from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised down by 40% over the last 30 days, indicating a reassessment by analysts of their initial estimates [4]. - The Most Accurate Estimate for Life360 aligns with the Zacks Consensus Estimate, resulting in an Earnings ESP of 0% [12]. Earnings Surprise Prediction - A positive Earnings ESP is generally a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1 (Strong Buy), 2 (Buy), or 3 (Hold) [10]. - Life360 currently holds a Zacks Rank of 4 (Sell), complicating the prediction of an earnings beat [12]. Historical Performance - Life360 has successfully beaten consensus EPS estimates in the last four quarters, with a notable surprise of +266.67% in the most recent quarter [13][14]. Conclusion - While Life360 is not positioned as a compelling earnings-beat candidate, investors are advised to consider other factors influencing stock performance ahead of the earnings release [17].

Core Viewpoint - Sarepta Therapeutics (SRPT) is anticipated to report a year-over-year decline in earnings due to lower revenues, with a consensus outlook indicating a quarterly loss of $0.71 per share, reflecting a -147.3% change from the previous year, and revenues expected to be $408.53 million, down 38% from the year-ago quarter [1][3]. Earnings Expectations - The upcoming earnings report is scheduled for February 25, and the stock may rise if the reported numbers exceed expectations, while a miss could lead to a decline [2]. - The consensus EPS estimate has been revised down by 45.87% over the last 30 days, indicating a reassessment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP (Expected Surprise Prediction) model suggests that the Most Accurate Estimate for Sarepta is higher than the Zacks Consensus Estimate, resulting in a positive Earnings ESP of +2.11% [12]. - The stock currently holds a Zacks Rank of 3, indicating a hold position, which suggests a likelihood of beating the consensus EPS estimate [12]. Historical Performance - In the last reported quarter, Sarepta was expected to post earnings of $0.01 per share but instead reported a loss of -$0.13, resulting in a surprise of -1,400.00% [13]. - Over the past four quarters, the company has only beaten consensus EPS estimates once [14]. Industry Context - In the broader context of the Zacks Medical - Biomedical and Genetics industry, Cytokinetics (CYTK) is also expected to report a loss of $1.48 per share, reflecting a year-over-year change of -17.5%, with revenues expected to be $3.89 million, down 77% from the previous year [18][19].

Wall Street expects a year-over-year increase in earnings on higher revenues when BKV (BKV) reports results for the quarter ended December 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on February 25. On the ...

Core Viewpoint - EuroDry (EDRY) is anticipated to report a year-over-year increase in earnings due to higher revenues for the quarter ending December 2025, with the consensus outlook indicating a significant potential impact on the stock price based on actual results compared to estimates [1][2]. Earnings Expectations - The Zacks Consensus Estimate predicts quarterly earnings of $0.78 per share, reflecting a year-over-year increase of +412% [3]. - Expected revenues are projected to be $16.51 million, which is a 13.8% increase from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised 2100% higher in the last 30 days, indicating a significant reassessment by analysts [4]. - The Most Accurate Estimate for EuroDry aligns with the Zacks Consensus Estimate, resulting in an Earnings ESP of 0% [12]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive or negative reading indicates the likely deviation of actual earnings from the consensus estimate, with a strong predictive power for positive readings [9][10]. - EuroDry currently holds a Zacks Rank of 1, but the combination with an Earnings ESP of 0% complicates predictions of an earnings beat [12]. Historical Performance - In the last reported quarter, EuroDry was expected to post a loss of $0.15 per share but instead reported a loss of -$0.23, resulting in a surprise of -53.33% [13]. - Over the past four quarters, the company has only beaten consensus EPS estimates once [14]. Conclusion - While EuroDry is not positioned as a compelling earnings-beat candidate, investors are advised to consider other factors when making decisions regarding the stock ahead of its earnings release [17].

Core Viewpoint - The market anticipates Domino's Pizza (DPZ) will report a year-over-year increase in earnings and revenues for the quarter ended December 2025, with actual results being crucial for stock price movement [1][2]. Earnings Expectations - Domino's Pizza is expected to post quarterly earnings of $5.36 per share, reflecting a year-over-year increase of +9.6% [3]. - Revenues are projected to reach $1.52 billion, which is a 4.9% increase from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised down by 0.11% over the last 30 days, indicating a reassessment by analysts [4]. - The Most Accurate Estimate for Domino's Pizza is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +2.88% [12]. Earnings Surprise Prediction - A positive Earnings ESP reading suggests a higher likelihood of an earnings beat, especially when combined with a Zacks Rank of 1, 2, or 3 [10]. - Domino's Pizza currently holds a Zacks Rank of 3, indicating a potential to beat the consensus EPS estimate [12]. Historical Performance - In the last reported quarter, Domino's Pizza exceeded the expected earnings of $3.96 per share by delivering $4.08, resulting in a surprise of +3.03% [13]. - Over the past four quarters, the company has beaten consensus EPS estimates two times [14]. Industry Context - Jack In The Box (JACK), a competitor in the Zacks Retail - Restaurants industry, is expected to report a significant decline in earnings per share of $1.1, down -42.7% year-over-year, with revenues expected to drop by 26.8% [18][19].

Core Viewpoint - Travere Therapeutics (TVTX) is anticipated to report a year-over-year increase in earnings and revenues for the quarter ending December 2025, which could significantly influence its stock price depending on the actual results compared to estimates [1][2]. Earnings Expectations - The consensus estimate for quarterly earnings is $0.03 per share, reflecting a year-over-year increase of +104.1% [3]. - Expected revenues are projected to be $142.46 million, representing a 90.5% increase from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised 17.07% higher in the last 30 days, indicating a positive reassessment by analysts [4]. - The Most Accurate Estimate for Travere is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +775.01%, suggesting a bullish outlook on the company's earnings [12]. Earnings Surprise Prediction - A positive Earnings ESP is a strong indicator of a potential earnings beat, especially when combined with a Zacks Rank of 1 (Strong Buy), 2 (Buy), or 3 (Hold) [10]. - Stocks with a positive Earnings ESP and a solid Zacks Rank have historically produced a positive surprise nearly 70% of the time [10]. Historical Performance - In the last reported quarter, Travere was expected to post a loss of $0.31 per share but instead reported earnings of $0.28, resulting in a surprise of +190.32% [13]. - Over the past four quarters, the company has exceeded consensus EPS estimates three times [14]. Conclusion - Travere is positioned as a compelling candidate for an earnings beat, but investors should consider other factors that may influence stock performance beyond earnings results [17].

Core Viewpoint - Ardelyx (ARDX) is anticipated to report flat earnings of $0.02 per share for the quarter ended December 2025, with revenues expected to reach $117.57 million, reflecting a 1.2% increase from the previous year [1][3]. Earnings Expectations - The upcoming earnings report is scheduled for February 19, and the stock may experience upward movement if earnings exceed expectations, while a miss could lead to a decline [2]. - The consensus EPS estimate has been revised down by 50% over the last 30 days, indicating a reassessment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model shows a positive Earnings ESP of +80.00% for Ardelyx, suggesting analysts have become more optimistic about the company's earnings prospects [12]. - The stock currently holds a Zacks Rank of 3, indicating a neutral outlook [12]. Historical Performance - In the last reported quarter, Ardelyx was expected to post a loss of $0.06 per share but instead delivered break-even earnings, resulting in a surprise of +100.00% [13]. - Over the past four quarters, the company has beaten consensus EPS estimates two times [14]. Conclusion - Ardelyx is viewed as a strong candidate for an earnings beat, but investors are advised to consider additional factors beyond earnings results when making investment decisions [17].

The market expects Yeti (YETI) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended December 2025. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on Fe ...